Trial Profile
Amifostine (Ethyol) to Reduce Mucositis, Decrease Haematological Toxicities, and Improve Salivary Sparing in Patients with Locally Advanced Head and Neck Cancer Treated with Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy (IMRT): A Phase II Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2013
Price :
$35
*
At a glance
- Drugs Amifostine (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Dec 2013 New trial record